A key pharmacy mental health trial funded under the 6CPA is set to commence shortly
The Pharmacy Guild of Australia, Pharmaceutical Society of Australia, Griffith University and the University of Sydney have announced that the Bridging the Gap between Physical and Mental Illness in Community Pharmacy (PharMIbridge) trial is set to commence in a few months’ time.
This study, co-led by pharmacy and mental health researchers Professor Amanda Wheeler (GU) and Dr Claire O’Reilly (USYD), focuses on individualised medicine support, adherence and mental and physical wellbeing for people living with severe and persistent mental illness such as schizophrenia, bipolar and severe depression.
National President of the Pharmacy Guild, George Tambassis, said community pharmacists are playing an increasingly important role in the area of mental health.
“As the most accessible of all health professionals, community pharmacists are often the first people mental health patients turn to for help and advice,” he said.
“Many pharmacists have undergone additional training to help them identify patients who may be living with mental illness.
“Pharmacists also are critical in helping patients adhere to their medicine regimens to ensure they get best possible outcomes from the medicines they have been prescribed.
“This project is an exciting and important initiative to broaden the role of pharmacists in helping patients with mental illness.”
PSA National President Associate Professor Chris Freeman said as medicines experts, pharmacists play a vital role in treating mental illness in the community.
“Medicines are an important component of treatment for people living with mental illness which is why pharmacists, as medicines experts, have a critical role to play, however that should not limit our role,” he said.
“Pharmacists serve as a critical element in the healthcare team, working with patients to manage their conditions, often as a conduit to other services, an advocate for the person, or to lend a compassionate ear.”
The RCT will be conducted in four study regions: Hunter New England and Northern Sydney regions in NSW, Gippsland region in Victoria, and the ACT.
Participating community pharmacies will be remunerated to support training attendance and to deliver either the PharMIbridge (intervention) or study funded MedsCheck (comparator) service.
Readers who would like further information can emailor visit
This project is part of the Pharmacy Trial Program funded under the Sixth Community Pharmacy Agreement.